Performance of the eHealth decision support tool, MIPOGG, for recognising children with Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin syndromes
-
Published:2023-07-17
Issue:12
Volume:60
Page:1218-1223
-
ISSN:0022-2593
-
Container-title:Journal of Medical Genetics
-
language:en
-
Short-container-title:J Med Genet
Author:
Hebert Robyn, Cullinan Noelle, Armstrong Linlea, Blood Katherine A, Brossard Josee, Brunga Ledia, Cacciotti Chantel, Caswell Kimberly, Cellot Sonia, Coltin Hallie, Deyell Rebecca J, Felton Kathleen, Fernandez Conrad V, Fleming Adam J, Gibson Paul, Hammad Rawan, Jabado NadaORCID, Johnston Donna L, Lafay-Cousin Lucie, Larouche Valérie, Leblanc-Desrochers Cassandra, Michaeli Orli, Perrier Renee, Pike Meghan, Say Jemma, Schiller Ian, Toupin Annie-Kim, Vairy Stéphanie, van Engelen Kalene, Waespe NicolasORCID, Villani Anita, Foulkes William DORCID, Malkin David, Reichman LaraORCID, Goudie Catherine
Abstract
BackgroundCancer predisposition syndromes (CPSs) are responsible for at least 10% of cancer diagnoses in children and adolescents, most of which are not clinically recognised prior to cancer diagnosis. A variety of clinical screening guidelines are used in healthcare settings to help clinicians detect patients who have a higher likelihood of having a CPS. The McGill Interactive Pediatric OncoGenetic Guidelines (MIPOGG) is an electronic health decision support tool that uses algorithms to help clinicians determine if a child/adolescent diagnosed with cancer should be referred to genetics for a CPS evaluation.MethodsThis study assessed MIPOGG’s performance in identifying Li-Fraumeni, DICER1, Constitutional mismatch repair deficiency and Gorlin (nevoid basal cell carcinoma) syndromes in a retrospective series of 84 children diagnosed with cancer and one of these four CPSs in Canadian hospitals over an 18-year period.ResultsMIPOGG detected 82 of 83 (98.8%) evaluable patients with any one of these four genetic conditions and demonstrated an appropriate rationale for suggesting CPS evaluation. When compared with syndrome-specific clinical screening criteria, MIPOGG’s ability to correctly identify children with any of the four CPSs was equivalent to, or outperformed, existing clinical criteria respective to each CPS.ConclusionThis study adds evidence that MIPOGG is an appropriate tool for CPS screening in clinical practice. MIPOGG’s strength is that it starts with a specific cancer diagnosis and incorporates criteria relevant for associated CPSs, making MIPOGG a more universally accessible diagnostic adjunct that does not require in-depth knowledge of each CPS.
Funder
Pediatric Oncology Group of Ontario Fonds de Recherche du Quebec - Santé Canadian Institutes of Health Research
Subject
Genetics (clinical),Genetics
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|